IPP Bureau
Biocon Biologics' new mAbs facility receives EU GMP Certification for bBevacizumab
By IPP Bureau - April 29, 2023
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
RPG Life Sciences posts Q4 revenue at Rs 118.49 Cr
By IPP Bureau - April 29, 2023
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Atul appoints Rangaswamy Iyer as Independent Director
By IPP Bureau - April 29, 2023
The appointment is effective from May 01, 2023 for five years
Evonik starts construction of new U.S. facility for pharmaceutical lipids
By IPP Bureau - April 29, 2023
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
TPAG organizes Thalassemia & SCD prevention discussion
By IPP Bureau - April 29, 2023
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
PI Industries announces twin acquisitions into Pharma API & CDMO space
By IPP Bureau - April 28, 2023
Laurus Labs Q4 FY23 consolidated PAT drops to to Rs. 102.98 Cr
By IPP Bureau - April 28, 2023
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Yuyu Pharma unveils the results of its studies for its dry eye treatment peptide
By IPP Bureau - April 28, 2023
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
Yasmin and Mirena to take back seat from Bayer’s future drug strategy, says GlobalData
By IPP Bureau - April 28, 2023
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Cipla partners with MNCs to strengthen anti-diabetes innovative portfolio: GlobalData
By IPP Bureau - April 28, 2023
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Ipca Laboratories gets 3 observations for Piparia, Silvassa unit
By IPP Bureau - April 27, 2023
The company will submit its comprehensive response on these observations to the US FDA within the stipulated time
Biocon approves NCD issue
By IPP Bureau - April 27, 2023
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
Syngene International posts Q4 FY2023 consolidated profit at Rs. 178.7 Cr
By IPP Bureau - April 27, 2023
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
Venus Remedies secures marketing authorization from UK MHRA for Cisplatin
By IPP Bureau - April 27, 2023
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
Siegfried breaks ground on new R&D center for drug substances in Switzerland
By IPP Bureau - April 26, 2023
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
